Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effect of Fingolimod on Neurodegeneration

Phase 4

Terminated

Conditions: Cognition
Brain Volume Loss

Interventions: Drug: 0,5 mg Fingolimod

First Posted Date: 2015-10-14

Last Posted Date: 2019-02-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 4

Registration Number: NCT02575365

Locations: 🇹🇷
Novartis Investigative Site, Kutahya, Turkey

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

Phase 3

Completed

Conditions: Sporadic Inclusion Body Myositis

Interventions: Drug: Bimagrumab
Drug: Placebo

First Posted Date: 2015-10-09

Last Posted Date: 2018-03-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 211

Registration Number: NCT02573467

Locations: 🇬🇧
Novartis Investigative Site, Newcastle upon Tyne, United Kingdom

Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: QVM149 150/50/80
Drug: salmeterol/fluticasone
Drug: QVM149 150/50/160
Drug: QMF149 150/320
Drug: QMF149 150/160

First Posted Date: 2015-10-08

Last Posted Date: 2020-07-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3092

Registration Number: NCT02571777

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients

Phase 1

Completed

Conditions: Anemia, Iron-Deficiency

Interventions: Biological: CSJ137
Drug: Placebo

First Posted Date: 2015-10-07

Last Posted Date: 2021-10-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT02570854

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma

Conditions: Multiple Myeloma

First Posted Date: 2015-10-06

Last Posted Date: 2020-04-08

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02568943

Locations: 🇸🇪
Novartis Investigative Site, Umea, Sweden

Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis

Phase 2

Completed

Conditions: Myasthenia Gravis, Generalized

Interventions: Drug: Placebo
Drug: CFZ533

First Posted Date: 2015-10-01

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 44

Registration Number: NCT02565576

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Phase 2

Terminated

Conditions: Alzheimers Disease

Interventions: Biological: CAD106 Immunotherapy
Other: Placebo to CAD106
Drug: CNP520
Other: Placebo to CNP520
Other: Alum

First Posted Date: 2015-10-01

Last Posted Date: 2021-07-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 480

Registration Number: NCT02565511

Locations: 🇺🇸
Banner Sun City Research Institute, Sun City, Arizona, United States
🇺🇸
California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States
🇺🇸
Advanced Clinical Research, Meridian, Idaho, United States

and more 56 locations

A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients

Phase 4

Completed

Conditions: COPD

Interventions: Drug: Indacaterol and glycopyrronium (QVA149)
Drug: Tiotropium

First Posted Date: 2015-10-01

Last Posted Date: 2019-09-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 379

Registration Number: NCT02566031

Locations: 🇰🇷
Novartis Investigative Site, Ulsan, Korea, Republic of

Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis

Phase 1

Completed

Conditions: Pulmonary Cystic Fibrosis

Interventions: Other: Placebo
Drug: QBW276

First Posted Date: 2015-10-01

Last Posted Date: 2020-12-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 16

Registration Number: NCT02566044

Locations: 🇩🇪
Novartis Investigative Site, Koeln, Germany

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: QAW039

First Posted Date: 2015-09-29

Last Posted Date: 2021-05-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 877

Registration Number: NCT02563067

Locations: 🇨🇳
Novartis Investigative Site, Taichung, Taiwan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy